|
Irhythm Technologies, Inc. (IRTC) DCF -Bewertung
US | Healthcare | Medical - Devices | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
iRhythm Technologies, Inc. (IRTC) Bundle
Erwerben Sie die Bewertungsanalyse für IRHYTHM Technologies, Inc. (IRTC) mit unserem hochmodernen DCF-Taschenrechner! Diese Excel -Vorlage wird mit tatsächlichen (IRTC-) Daten vorinstalliert, sodass Sie Prognosen und Annahmen anpassen können, um den inneren Wert von Irhythm Technologies, Inc. genau zu bestimmen.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 265.2 | 322.8 | 410.9 | 492.7 | 591.8 | 723.6 | 884.7 | 1,081.7 | 1,322.5 | 1,617.0 |
| Revenue Growth, % | 0 | 21.74 | 27.29 | 19.9 | 20.13 | 22.26 | 22.26 | 22.26 | 22.26 | 22.26 |
| EBITDA | -29.2 | -83.2 | -92.1 | -96.9 | -74.1 | -132.3 | -161.7 | -197.7 | -241.7 | -295.5 |
| EBITDA, % | -10.99 | -25.78 | -22.42 | -19.66 | -12.52 | -18.28 | -18.28 | -18.28 | -18.28 | -18.28 |
| Depreciation | 12.9 | 16.6 | 19.6 | 22.1 | 25.8 | 34.2 | 41.8 | 51.1 | 62.5 | 76.4 |
| Depreciation, % | 4.88 | 5.14 | 4.77 | 4.49 | 4.36 | 4.73 | 4.73 | 4.73 | 4.73 | 4.73 |
| EBIT | -42.1 | -99.8 | -111.7 | -119.0 | -99.9 | -166.5 | -203.5 | -248.8 | -304.2 | -372.0 |
| EBIT, % | -15.87 | -30.92 | -27.19 | -24.15 | -16.88 | -23 | -23 | -23 | -23 | -23 |
| Total Cash | 335.2 | 239.1 | 213.1 | 133.8 | 535.6 | 497.2 | 607.9 | 743.3 | 908.8 | 1,111.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 29.9 | 46.4 | 49.9 | 61.5 | 79.9 | 92.3 | 112.9 | 138.0 | 168.8 | 206.3 |
| Account Receivables, % | 11.29 | 14.38 | 12.15 | 12.48 | 13.51 | 12.76 | 12.76 | 12.76 | 12.76 | 12.76 |
| Inventories | 5.3 | 10.3 | 15.2 | 14.0 | 14.0 | 20.4 | 24.9 | 30.5 | 37.2 | 45.5 |
| Inventories, % | 2 | 3.18 | 3.69 | 2.84 | 2.37 | 2.82 | 2.82 | 2.82 | 2.82 | 2.82 |
| Accounts Payable | 4.4 | 10.5 | 7.5 | 5.5 | 7.2 | 13.1 | 16.1 | 19.6 | 24.0 | 29.4 |
| Accounts Payable, % | 1.65 | 3.26 | 1.83 | 1.13 | 1.22 | 1.82 | 1.82 | 1.82 | 1.82 | 1.82 |
| Capital Expenditure | -13.6 | -28.1 | -29.8 | -40.4 | .0 | -42.4 | -51.8 | -63.3 | -77.4 | -94.7 |
| Capital Expenditure, % | -5.11 | -8.69 | -7.26 | -8.2 | 0 | -5.85 | -5.85 | -5.85 | -5.85 | -5.85 |
| Tax Rate, % | -0.50122 | -0.50122 | -0.50122 | -0.50122 | -0.50122 | -0.50122 | -0.50122 | -0.50122 | -0.50122 | -0.50122 |
| EBITAT | -42.3 | -100.2 | -112.0 | -119.7 | -100.4 | -166.5 | -203.5 | -248.8 | -304.2 | -372.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -73.8 | -127.0 | -133.6 | -150.4 | -91.5 | -187.4 | -235.7 | -288.1 | -352.3 | -430.7 |
| WACC, % | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,120.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -439 | |||||||||
| Terminal Value | -6,234 | |||||||||
| Present Terminal Value | -4,043 | |||||||||
| Enterprise Value | -5,163 | |||||||||
| Net Debt | 317 | |||||||||
| Equity Value | -5,481 | |||||||||
| Diluted Shares Outstanding, MM | 31 | |||||||||
| Equity Value Per Share | -175.68 |
What You Will Get
- Real IRTC Financial Data: Pre-filled with iRhythm Technologies’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See iRhythm Technologies’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for iRhythm Technologies, Inc. (IRTC).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with customizable inputs specific to (IRTC).
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit (IRTC) projections.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to iRhythm Technologies, Inc. (IRTC).
- Visual Dashboard and Charts: Graphical outputs present key valuation metrics for straightforward analysis of (IRTC).
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered iRhythm Technologies, Inc. (IRTC) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for iRhythm Technologies, Inc. (IRTC)’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose iRhythm Technologies, Inc. (IRTC)?
- Innovative Technology: Leverage cutting-edge solutions for cardiac monitoring and data analysis.
- Enhanced Patient Care: Accurate and timely insights improve diagnosis and treatment outcomes.
- User-Friendly Interface: Intuitive design allows for easy navigation and efficient usage.
- Robust Data Security: Comprehensive measures ensure the protection of sensitive patient information.
- Industry Leader: Trusted by healthcare professionals for reliable cardiac monitoring solutions.
Who Should Use This Product?
- Investors: Evaluate iRhythm Technologies, Inc. (IRTC) to make informed stock trading decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts.
- Startup Founders: Understand the valuation strategies of established companies like iRhythm Technologies.
- Consultants: Provide comprehensive valuation analyses and reports for your clientele.
- Students and Educators: Utilize current market data to enhance learning and teaching of valuation principles.
What the Template Contains
- Pre-Filled Data: Contains iRhythm Technologies’ historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model with automated calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for computing WACC based on user-defined inputs.
- Key Financial Ratios: Evaluate iRhythm Technologies’ profitability, efficiency, and leverage.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
- Clear Dashboard: Visuals and tables summarizing essential valuation outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.